8-K: Arbutus Biopharma and Genevant Sciences Launch International Patent Enforcement Actions Against Moderna

Arbutus Biopharma and Genevant Sciences are intensifying their legal battle against Moderna by filing international lawsuits to protect their lipid nanoparticle (LNP) technology.

Summary

• Arbutus Biopharma and Genevant Sciences have initiated five international lawsuits against Moderna and its affiliates.
• The lawsuits aim to enforce patents protecting their lipid nanoparticle (LNP) technology.
• The enforcement actions target alleged infringing activities in 30 countries.
• The companies are seeking monetary relief and injunctions against Moderna's Spikevax and mRESVIA products.
• Arbutus has also notified Moderna of its intent to terminate a non-exclusive license agreement due to alleged material breach related to milestone and royalty payments for mRESVIA.
• Arbutus and Genevant have agreed that Arbutus is entitled to any damages awarded in the patent litigation specifically allocated to Moderna's mRESVIA vaccine.
• If damages are not specifically allocated to mRESVIA, the parties will discuss an appropriate allocation in good faith.

Sentiment

Score: 5

Explanation: The announcement is neutral. It details legal actions, which have both potential upside (monetary relief) and downside (legal costs and uncertainty).

Positives

• Arbutus is actively defending its intellectual property rights through international lawsuits.
• The agreement with Genevant ensures Arbutus will receive any damages specifically allocated to mRESVIA in the patent litigation.
• The termination of the non-exclusive license agreement with Moderna could potentially increase the value of Genevant's license under the Cross License Agreement.

Negatives

• The outcome of the lawsuits is uncertain and could involve significant legal costs.
• The termination of the license agreement could lead to further legal disputes with Moderna.
• The success of the patent enforcement actions is dependent on proving infringement and the validity of the patents.

Risks

• The patent litigation may not be successful, resulting in no monetary recovery for Arbutus and Genevant.
• Moderna may successfully defend against the patent infringement claims.
• The legal proceedings could be lengthy and expensive, impacting Arbutus's financial resources.
• The termination of the license agreement could negatively impact Arbutus's relationship with Moderna.

Future Outlook

Arbutus plans to continue pursuing patent litigation against Moderna and enforcing its intellectual property rights. The company will also continue developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV).

Industry Context

The lawsuits highlight the increasing importance of intellectual property protection in the pharmaceutical industry, particularly in the development of mRNA-based therapies and vaccines. The outcome of these cases could have significant implications for the competitive landscape and licensing agreements in the industry.

Comparison to Industry Standards

• The legal actions taken by Arbutus and Genevant are consistent with industry practices for protecting intellectual property rights.
• Other companies in the pharmaceutical and biotechnology sectors, such as Pfizer and BioNTech, have also engaged in patent litigation to defend their innovations.
• The success of Arbutus and Genevant's lawsuits will depend on the strength of their patents and the evidence of infringement by Moderna, similar to other high-profile patent disputes in the industry.

Legal Proceedings

• Arbutus and Genevant have filed five international lawsuits against Moderna for patent infringement.
• Arbutus has notified Moderna of its intent to terminate a non-exclusive license agreement due to alleged material breach.
• There is ongoing enforcement proceeding in the U.S. District Court for the District of Delaware, with a jury trial scheduled for September 2025.

Stakeholder Impact

• Shareholders of Arbutus and Genevant may be impacted by the outcome of the patent litigation.
• The lawsuits could affect Moderna's ability to manufacture and sell its Spikevax and mRESVIA products.
• The legal proceedings could impact the competitive landscape of the mRNA vaccine market.

Next Steps

• Arbutus and Genevant will continue to pursue the international lawsuits against Moderna.
• Moderna has 60 days to cure the alleged breach of the sublicense agreement.
• The jury trial in the U.S. District Court for the District of Delaware is scheduled for September 2025.

Key Dates